ArticlemBio2021
Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- Egg-Derived Anti-SARS-CoV-2 Immunoglobulin Y (IgY) With Broad Variant Activity as Intranasal Prophylaxis Against COVID-19.Frontiers in immunology · 2022Trial
- Article
- SARS-CoV-2 RBD Scaffolded by AP205 or TIP60 Nanoparticles and Delivered as mRNA Elicits Robust Neutralizing Antibody Responses.Vaccines · 2025Article
- Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating themBio · 2024Article
- Review
- A ferritin-based nanoparticle displaying a neutralizing epitope for foot-and-mouth disease virus (FMDV) confers partial protection in guinea pigs.BMC veterinary research · 2024Article
- Article
- Review
- A Self-Assembling Pfs230D1-Ferritin Nanoparticle Vaccine Has Potent and Durable Malaria Transmission-Reducing Activity.Vaccines · 2024Article
- Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment.Signal transduction and targeted therapy · 2024Review
- Current Progress of Severe Fever with Thrombocytopenia Syndrome Virus (SFTSV) Vaccine Development.Viruses · 2024Review
- Advances in virus-like particle-based SARS-CoV-2 vaccines.Frontiers in cellular and infection microbiology · 2024Review
- Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.Frontiers in immunology · 2024Review
- Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5.Vaccines · 2023Article
- Recombinant ferritins for multimodal nanomedicine.Journal of enzyme inhibition and medicinal chemistry · 2023Review
- Adjuvanted-SARS-CoV-2 Spike Protein-Based Microparticulate Vaccine Delivered by Dissolving Microneedles Induces Humoral, Mucosal, and Cellular Immune Responses in Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.International journal of biological macromolecules · 2023Review
- Article
- Ferrets: A powerful model of SARS-CoV-2.Zoological research · 2023Review
- Ferritin nanocages as efficient nanocarriers and promising platforms for COVID-19 and other vaccines development.Biochimica et biophysica acta. General subjects · 2023Review
Corrections and comments
- Update of
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a causative agent of the CoV disease 2019 (COVID-19) pandemic, enters host cells via the interaction of its receptor-binding domain (RBD) of the spike protein with host angiotensin-converting enzyme 2 (ACE2). Therefore, the RBD is a promising vaccine target to induce protective immunity against SARS-CoV-2 infection. In this study, we report the development of an RBD protein-based vaccine candidate against SARS-CoV-2 using self-assembling
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.